171048-63-8

Basic information

• Product Name: 6-benzyl-5-ethylpyrimidine-2,4(1H,3H)-dione
• Synonyms: 6-benzyl-5-ethylpyrimidine-2,4(1H,3H)-dione
• CAS NO: 171048-63-8
• Molecular Weight: 230.266
• Mol File: 171048-63-8.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 6-benzyl-5-ethylpyrimidine-2,4(1H,3H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 6-benzyl-5-ethylpyrimidine-2,4(1H,3H)-dione(171048-63-8)
• EPA Substance Registry System: 6-benzyl-5-ethylpyrimidine-2,4(1H,3H)-dione(171048-63-8)

Safety Data

• Hazardous Substances Data: 171048-63-8(Hazardous Substances Data)

Upstream product

• 103-80-0 phenylacetyl chloride 
• 718-08-1 ethyl 3-oxo-4-phenylbutyrate 
• 140-29-4 phenylacetonitrile 
• 171855-61-1 ethyl 2-ethyl-3-oxo-4-phenylbutanoate 
• 6921-34-2 benzylmagnesium chloride 
• 225232-00-8 6-benzyl-2,4-dichloro-5-ethylpyrimidine 
• 1780-38-7 2,4,6-trichloro-5-ethylpyrimidine 
• 225232-54-2 6-benzyl-2,4-dimethoxy-5-ethylpyrimidine 
• 199851-89-3 6-benzyl-5-ethyl-2-thiouracil 

Downstream Products

• 1254831-93-0 6-benzyl-1-(benzyloxymethyl)-5-ethylpyrimidine-2,4(1H,3H)-dione 
• 1254831-84-9 6-benzyl-1-(benzyloxymethyl)-5-ethyl-3-hydroxypyrimidine-2,4(1H,3H)-dione 
• 1281860-01-2 6-benzyl-5-ethyl-1-(4-fluorobenzyl)pyrimidine-2,4(1H,3H)-dione 
• 1281860-00-1 1,6-dibenzyl-5-ethylpyrimidine-2,4(1H,3H)-dione 
• 1202175-26-5 6-benzyl-5-ethyl-1-(3-phenylprop-1-yloxymethyl)uracil 
• 1202175-22-1 6-benzyl-5-ethyl-1-(2-phenylethyloxymethyl)uracil 
• 1202175-18-5 6-benzyl-1-cyclopropylmethyloxymethyl-5-ethyluracil 
• 444788-55-0 1-(2-acetoxyethoxymethyl)-6-benzyl-5-ethyluracil 
• 1055031-79-2 6-Benzyl-1-[(2S,5S)-5-(tert-butyl-diphenyl-silanyloxymethyl)-tetrahydro-furan-2-yl]-5-ethyl-1H-pyrimidine-2,4-dione 
• 176519-58-7 Thiocarbonic acid O-[(2R,3S,5R)-5-(6-benzyl-5-ethyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2-(tert-butyl-diphenyl-silanyloxymethyl)-tetrahydro-furan-3-yl] ester O-phenyl ester 
• 176519-59-8 Thiocarbonic acid O-[(2R,3S,5S)-5-(6-benzyl-5-ethyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2-(tert-butyl-diphenyl-silanyloxymethyl)-tetrahydro-furan-3-yl] ester O-phenyl ester 
• 136160-29-7 5-ethyl-1-ethoxymethyl-6-(benzyl)uracil 

Relevant articles and documents

Synthesis and Antiviral Evaluation of 1-[(2-Phenoxyethyl)oxymethyl] and 6-(3,5-Dimethoxybenzyl) Analogues of HIV Drugs Emivirine and TNK-651

Novel emivirine analogues 6a, b were synthesized by reacting chloromethyl ethyl ether with 5-ethyl/isopropyl-6-(3,5-dimethoxybenzyl)uracils 5e, f. On the other hand, A series of new TNK-651 analogues 10a-f substituted at N-1 with phenoxyethoxymethyl moiety was prepared on treatment of the corresponding uracils 5a-f with bis(phenoxyethoxy)methane (9). The newly synthesized non-nucleosides were tested for antiviral activity against wild type HIV-1 IIIB as well as the resistant strains N119 (Y181C), A17 (K103N+Y181C), and the triple mutant EFVR (K103R+V179D+P225H) in MT-4 cells. Most of the tested compounds showed good activities. Among them 6-(3,5-dimethylbenzyl)-5-ethyl-1-[(2-phenoxyethyl)oxymethyl]uracil (10c) and 6-(3,5-dimethylbenzyl)-5-isopropyl-1-[(2-phenoxyethyl)oxymethyl]uracil (10d) that showed inhibitory potency higher than emivirine against both wild type HIV-1 and the tested mutant strains, as well as higher activity than efavirenz against EFVR.

N-3 hydroxylation of pyrimidine-2,4-diones yields dual inhibitors of HIV reverse transcriptase and integrase

A new molecular scaffold featuring an N-hydroxyimide functionality and capable of inhibiting both reverse transcriptase (RT) and integrase (IN) of human immunodeficiency virus (HIV) was rationally designed based on 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) non-nucleoside RT inhibitors (NNRTIs). The design involves a minimal 3-N hydroxylation of the pyrimidine ring of HEPT compound to yield a chelating triad which, along with the existing benzyl group, appeared to satisfy major structural requirements for IN binding. In the mean time, this chemical modification did not severely compromise the compound's ability to inhibit RT. A preliminary structure-activity relationship (SAR) study reveals that this N-3 OH is essential for IN inhibition and that the benzyl group on N-1 side chain is more important for IN binding than the one on C-6.

Pyrimidine acyclonucleoside derivatives, preparation method and use thereof

The invention relates to a compound having general formula (I): wherein n is equal to 3; R1 is an ethyl or isopropyl group; each of the R2 groups is independently of each other a hydrogen atom, a C1-C3 alkyl group or a halogen atom; one of the R3 and R4 groups represents a hydrogen atom while the other of the R3 and R4 groups represents an OH or OR5 group, where R5 can be a C2-C7 acyl group, an alkyl(C1-C6)animo-carbonyl group, an aralkyl(C1-C6)aminocarbonyl optionally substituted on the aryl, an arylcarbonyl group optionally substituted or a heteroarylaminocarbonyl group. Said compound is particularly suitable as an antiviral agent and especially as an anti-HIV-1 agent.